Final Cerebral Infarct Volume Is Predictable by MR Imaging at 1 Week

References

1. 1.↵
   1. Phan TG,
   2. Donnan GA,
   3. Davis SM,
   4. et al

   . Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke 2006;37:2521–25

   Abstract/FREE Full Text
2. 2.↵
   1. Warach S,
   2. Pettigrew LC,
   3. Dashe JF,
   4. et al

   . Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging: citicoline 010 investigators. Ann Neurol 2000;48:713–22

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Warach S,
   2. Kaufman D,
   3. Chiu D,
   4. et al

   . Effect of the glycine antagonist gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The Gain MRI Substudy. Cerebrovasc Dis 2006;21:106–11. Epub 2005 Dec 9

   PubMed
4. 4.↵
   1. Smith JJ,
   2. Sorensen AG,
   3. Thrall JH

   . Biomarkers in imaging: realizing radiology's future. Radiology 2003;227:633–38

   PubMedWeb of Science
5. 5.↵
   1. Wintermark M,
   2. Albers GW,
   3. Alexandrov AV,
   4. et al

   . Acute stroke imaging research roadmap. Stroke 2008;39:1621–28

   Abstract/FREE Full Text
6. 6.↵
   1. Albers GW,
   2. Thijs VN,
   3. Wechsler L,
   4. et al

   . Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (defuse) study. Ann Neurol 2006;60:508–17

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Davis SM,
   2. Donnan GA,
   3. Parsons MW,
   4. et al

   . Effects of alteplase beyond 3 h after stroke in the echo-planar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299–309

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Gaudinski MR,
   2. Henning EC,
   3. Miracle A,
   4. et al

   . Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. Stroke 2008;39:2765–68

   Abstract/FREE Full Text
9. 9.↵
   1. Lansberg MG,
   2. O'Brien MW,
   3. Tong DC,
   4. et al

   . Evolution of cerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. Arch Neurol 2001;58:613–17

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Tourdias T,
    2. Dousset V,
    3. Sibon I,
    4. et al

    . Magnetization transfer imaging shows tissue abnormalities in the reversible penumbra. Stroke 2007;38:3165–71

    Abstract/FREE Full Text
11. 11.↵
    1. Renou P,
    2. Sibon I,
    3. Tourdias T,
    4. et al

    . Reliability of the ECASS radiological classification of postthrombolysis brain haemorrhage: a comparison of CT and three MRI sequences. Cerebrovasc Dis 2010;29:597–604. Epub 2010 Apr 23

    CrossRefPubMed
12. 12.↵
    1. Sibon I,
    2. Menegon P,
    3. Orgogozo JM,
    4. et al

    . Inter- and intraobserver reliability of five MRI sequences in the evaluation of the final volume of cerebral infarct. J Magn Reson Imaging 2009;29:1280–84

    CrossRefPubMed
13. 13.↵
    1. Sobesky J,
    2. Zaro Weber O,
    3. Lehnhardt FG,
    4. et al

    . Which time-to-peak threshold best identifies penumbral flow? A comparison of perfusion-weighted magnetic resonance imaging and positron emission tomography in acute ischemic stroke. Stroke 2004;35:2843–47

    Abstract/FREE Full Text
14. 14.↵
    1. Neumann-Haefelin T,
    2. Wittsack HJ,
    3. Wenserski F,
    4. et al

    . Diffusion- and perfusion-weighted MRI: the DWI/PWI mismatch region in acute stroke. Stroke 1999;30:1591–97

    Abstract/FREE Full Text
15. 15.↵
    1. Hosmer D,
    2. Lemeshow S

    . Applied Logistic Regression.2nd ed. New York: John Wiley and Sons; 2000
16. 16.↵
    1. Kasner SE

    . Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603–12

    CrossRefPubMedWeb of Science
17. 17.↵
    Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–87

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Hacke W,
    2. Kaste M,
    3. Bluhmki E,
    4. et al

    . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29

    CrossRefPubMedWeb of Science
19. 19.↵
    1. van der Worp HB,
    2. Kappelle LJ,
    3. Algra A,
    4. et al.,
    5. the TESS Investigators; TESS II Investigators

    . The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology 2002;58:133–35

    Abstract/FREE Full Text
20. 20.↵
    1. Beaulieu C,
    2. de Crespigny A,
    3. Tong DC,
    4. et al

    . Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol 1999;46:568–78

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Ebinger M,
    2. Christensen S,
    3. De Silva DA,
    4. et al

    . Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke 2009;40:1353–58

    Abstract/FREE Full Text
22. 22.↵
    1. Schiemanck SK,
    2. Post MW,
    3. Kwakkel G,
    4. et al

    . Ischemic lesion volume correlates with long-term functional outcome and quality of life of middle cerebral artery stroke survivors. Restor Neurol Neurosci 2005;23:257–63

    PubMedWeb of Science
23. 23.↵
    1. Saver JL,
    2. Johnston KC,
    3. Homer D,
    4. et al

    . Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials: The RANTTAS Investigators. Stroke 1999;30:293–98

    Abstract/FREE Full Text
24. 24.↵
    1. Barrett KM,
    2. Ding YH,
    3. Wagner DP,
    4. et al.,
    5. ASAP Investigators

    . Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke 2009;40:2422–7. Epub 2009 May 14

    Abstract/FREE Full Text
25. 25.↵
    1. Thijs VN,
    2. Lansberg MG,
    3. Beaulieu C,
    4. et al

    . Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis. Stroke 2000;31:2597–602

    Abstract/FREE Full Text
26. 26.↵
    1. Pillai JJ

    . Insights into adult postlesional language cortical plasticity provided by cerebral blood oxygen level-dependent functional MR imaging. AJNR Am J Neuroradiol 2010;31:990–96. Epub 2009 Dec 10

    Abstract/FREE Full Text
27. 27.↵
    1. Cipriano LE,
    2. Steinberg ML,
    3. Gazelle GS,
    4. et al

    . Comparing and predicting the costs and outcomes of patients with major and minor stroke using the Boston Acute Stroke Imaging Scale neuroimaging classification system. AJNR Am J Neuroradiol 2009;30:703–09. Epub 2009 Jan 22

    Abstract/FREE Full Text
28. 28.↵
    1. Rha JH,
    2. Saver JL

    . The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–73

    Abstract/FREE Full Text
29. 29.↵
    1. Sormani MP,
    2. Bruzzi P,
    3. Comi G,
    4. et al

    . MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002;58:417–21

    Abstract/FREE Full Text
30. 30.↵
    1. Orgogozo JM

    . The concepts of impairment, disability and handicap. Cerebrovasc Dis 1994;4(suppl):2–6
31. 31.↵
    1. Duncan PW,
    2. Jorgensen HS,
    3. Wade DT

    . Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000;31:1429–38

    Abstract/FREE Full Text
32. 32.↵
    1. Prentice RL

    . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431–40

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Merino JG,
    2. Latour LL,
    3. Todd JW,
    4. et al

    . Lesion volume change after treatment with tissue plasminogen activator can discriminate clinical responders from nonresponders. Stroke 2007;38:2919–23

    Abstract/FREE Full Text
34. 34.↵
    1. Rother J,
    2. Schellinger PD,
    3. Gass A,
    4. et al

    . Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002;33:2438–45

    Abstract/FREE Full Text
35. 35.↵
    1. Chalela JA,
    2. Kang DW,
    3. Luby M,
    4. et al

    . Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol 2004;55:105–12

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Barber PA,
    2. Parsons MW,
    3. Desmond PM,
    4. et al

    . The use of PWI and DWI measures in the design of “proof-of-concept” stroke trials. J Neuroimaging 2004;14:123–32

    CrossRefPubMed